These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 38922326

  • 1. R229I substitution from oseltamivir induction in HA1 region significantly increased the fitness of a H7N9 virus bearing NA 292K.
    Tang J, Zou SM, Zhou JF, Gao RB, Xin L, Zeng XX, Huang WJ, Li XY, Cheng YH, Liu LQ, Xiao N, Wang DY.
    Emerg Microbes Infect; 2024 Dec; 13(1):2373314. PubMed ID: 38922326
    [Abstract] [Full Text] [Related]

  • 2. Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
    Tang J, Gao R, Liu L, Zhang S, Liu J, Li X, Fang Q, Feng Z, Xu C, Huang W, Wang D.
    Sci Rep; 2021 Aug 11; 11(1):16293. PubMed ID: 34381119
    [Abstract] [Full Text] [Related]

  • 3. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
    Tang J, Zhang J, Zhou J, Zhu W, Yang L, Zou S, Wei H, Xin L, Huang W, Li X, Cheng Y, Wang D.
    Virol J; 2019 Jul 02; 16(1):87. PubMed ID: 31266524
    [Abstract] [Full Text] [Related]

  • 4. Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
    Tang J, Zhang SX, Zhang J, Li XY, Zhou JF, Zou SM, Bo H, Xin L, Yang L, Liu J, Huang WJ, Dong J, Wang DY.
    Virology; 2020 Oct 02; 549():77-84. PubMed ID: 32853849
    [Abstract] [Full Text] [Related]

  • 5. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
    Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, Fry AM, Gubareva LV.
    J Virol; 2015 May 02; 89(10):5419-26. PubMed ID: 25740997
    [Abstract] [Full Text] [Related]

  • 6. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
    Marjuki H, Mishin VP, Chesnokov AP, Jones J, De La Cruz JA, Sleeman K, Tamura D, Nguyen HT, Wu HS, Chang FY, Liu MT, Fry AM, Cox NJ, Villanueva JM, Davis CT, Gubareva LV.
    J Infect Dis; 2015 Jan 15; 211(2):249-57. PubMed ID: 25124927
    [Abstract] [Full Text] [Related]

  • 7. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
    Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, Zhou J, Ng IH, Zhu H, Webby RJ, Guan Y, Webster RG, Peiris JS.
    mBio; 2013 Jul 16; 4(4):. PubMed ID: 23860768
    [Abstract] [Full Text] [Related]

  • 8. Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Suzuki S, Shichinohe S, Itoh Y, Nakayama M, Ishigaki H, Mori Y, Ogata-Nakahara A, Nguyen CT, Okamatsu M, Sakoda Y, Kida H, Ogasawara K.
    Antiviral Res; 2020 Jun 16; 178():104790. PubMed ID: 32272175
    [Abstract] [Full Text] [Related]

  • 9. A Single Amino Acid Substitution at Residue 218 of Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate Vaccine Viruses.
    Li X, Gao Y, Ye Z.
    J Virol; 2019 Oct 01; 93(19):. PubMed ID: 31270231
    [Abstract] [Full Text] [Related]

  • 10. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
    Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM.
    Nat Commun; 2013 Oct 01; 4():2854. PubMed ID: 24326875
    [Abstract] [Full Text] [Related]

  • 11. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R, Butler J, Reading PC, Hurt AC.
    Antiviral Res; 2019 Aug 01; 168():68-75. PubMed ID: 31132385
    [Abstract] [Full Text] [Related]

  • 12. The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
    Ge Y, Chi Y, Min X, Zhao K, Wu B, Wu T, Zhu X, Shi Z, Zhu F, Cui L.
    Virology; 2019 Oct 01; 536():58-67. PubMed ID: 31400550
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X, Landreth S, Lu Y, Pandey K, Zhou Y.
    J Virol; 2021 Jan 13; 95(3):. PubMed ID: 33177192
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
    Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV.
    Emerg Infect Dis; 2013 Jan 13; 19(9):1521-4. PubMed ID: 23965618
    [Abstract] [Full Text] [Related]

  • 17. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
    Liu Q, Ma J, Strayer DR, Mitchell WM, Carter WA, Ma W, Richt JA.
    Expert Rev Anti Infect Ther; 2014 Feb 13; 12(2):165-9. PubMed ID: 24350808
    [Abstract] [Full Text] [Related]

  • 18. Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017.
    Zhu W, Zhou J, Li Z, Yang L, Li X, Huang W, Zou S, Chen W, Wei H, Tang J, Liu L, Dong J, Wang D, Shu Y.
    Euro Surveill; 2017 May 11; 22(19):. PubMed ID: 28537546
    [Abstract] [Full Text] [Related]

  • 19. PCR for detection of oseltamivir resistance mutation in influenza A(H7N9) virus.
    Wang W, Song Z, Guan W, Liu Y, Zhang X, Xu L, Li J, Yuan Z, Hu Y.
    Emerg Infect Dis; 2014 May 11; 20(5):847-9. PubMed ID: 24751348
    [Abstract] [Full Text] [Related]

  • 20. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
    Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.
    Antimicrob Agents Chemother; 2012 Mar 11; 56(3):1208-14. PubMed ID: 22203589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.